ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is set to release its earnings data before the market opens on Friday, May 10th. Analysts expect ANI Pharmaceuticals to post earnings of $0.98 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.26-4.67 EPS and its FY 2024 guidance at 4.260-4.670 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:ANIP opened at $65.62 on Thursday. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of 78.12 and a beta of 0.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81. The business’s 50-day moving average is $66.96 and its 200-day moving average is $59.36. ANI Pharmaceuticals has a 1 year low of $38.91 and a 1 year high of $70.81.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent analyst reports. Capital One Financial initiated coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. HC Wainwright increased their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Truist Financial boosted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Guggenheim reiterated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $80.00.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 7,414 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the sale, the chief operating officer now directly owns 825,206 shares in the company, valued at approximately $54,735,913.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 28,965 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total value of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Muthusamy Shanmugam sold 7,414 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the transaction, the chief operating officer now owns 825,206 shares of the company’s stock, valued at $54,735,913.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 176,803 shares of company stock worth $11,695,866. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.